Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Haitong Int'l Securities (665 HK): A 114% Offer Premium Should Do The Trick

Haitong Int'l Securities (665 HK): Possible Offer From Parent

Quiddity Advisors

Event-Driven

Haitong International Securities Group / Event-Driven

Haitong International Securities Group (665 HK)

<ul>
<li>Once the pre-cons were satisfied on the 15th November, it seemed pessimistic to stick to the delayed 29 December dispatch date for <strong><a href="https://www.smartkarma.com/entities/haitong-international-securities-group-ltd" target="_blank" data-smartkarma-citation="entities:13153:1" rel="noopener">Haitong International Securities Group (665 HK)</a></strong>'s Scheme Document. </li>
<li>And right on cue, the Doc was issued last night (21 Nov). The Court Meeting is the 15 December. with an expected cash despatch on or around the 18 January.</li>
<li>Trading at a gross spread to terms of 2.7%. The headcount test applies. But this should comfortably get up. </li>
</ul>


Once the pre-cons were satisfied on the 15th November, it seemed pessimistic to stick to the delayed 29 December dispatch date for Haitong International Securities Group (665 HK)'s Scheme Document. 
And right on cue, the Doc was issued last night (21 Nov). The Court Meeting is the 15 December. with an expected cash despatch on or around the 18 January.
Trading at a gross spread to terms of 2.7%. The headcount test applies. But this should comfortably get up. 


Haitong Securities Co Ltd (A) (600837 CH)

Lansen Pharmaceutical Holdings Co, Ltd. (503 HK)

Haitong Sec (665 HK) 15th Dec Scheme Vote